Virometix AG

About Virometix AG

Virometix AG is a clinical stage biotech company focused on developing a new class of synthetic vaccines to combat infectious diseases and cancer. Their vaccines are designed to elicit a precise, robust, and sustained immune response using a proprietary modular and fully synthetic nanoparticle technology platform, which is safe, cost-effective, and scalable.

Products & Services

Synthetic Vaccines for Streptococcus pneumoniae:A serotype-independent vaccine candidate targeting a high unmet need for Streptococcus pneumoniae infections.

Synthetic Vaccines for RSV:A first-in-class vaccine candidate for Respiratory Syncytial Virus (RSV).

Synthetic Vaccines for Coronaviruses:Prophylactic approaches for Coronaviruses using their synthetic nanoparticle platform.

Nanoparticle Technology Platform:A modular synthetic platform for designing safe and efficacious vaccines with multivalent immunogens mimicking protective epitopes.

Specialties

Synthetic Vaccines Nanoparticle Technology Infectious Diseases Cancer Vaccines Immunogen Design

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Financing Round T: - FT: Financing Round	A: 15000000 MR: - FA: $15 million FAN: 15000000	D: 2025-11-13 FD: 2025-11-13	1 investors

Financing Round Latest

2025-11-13

$15.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Anna Sumeray

Chief Executive Officer

M

Marc Mansour

Chief Technical Officer

L

Lilli Stergiou

Chief Scientific Officer

M

Markus Heck

Head of Technical Operations

M

Mark Sumeray

Chief Medical Officer

J

Jan ter Meulen

Chair of Research

View 11 more team members with Pro

Unlock Full Team Directory

Recent News

Virometix AG Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised